Citadel Advisors
BEAM icon

Citadel Advisors’s Beam Therapeutics BEAM Stock Holding History

Citadel Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.07M Buy
44,700
+10,500
+31% +$291K ﹤0.01% 7516
2025
Q4 		$948K Sell
34,200
-98,900
-74% -$2.52M ﹤0.01% 7511
2025
Q3 		$3.23M Sell
133,100
-113,000
-46% -$2.25M ﹤0.01% 5173
2025
Q2 		$4.19M Buy
246,100
+97,600
+66% +$1.7M ﹤0.01% 4418
2025
Q1 		$2.9M Buy
148,500
+78,800
+113% +$2.06M ﹤0.01% 4822
2024
Q4 		$1.73M Buy
69,700
+10,600
+18% +$271K ﹤0.01% 5934
2024
Q3 		$1.45M Sell
59,100
-27,300
-32% -$705K ﹤0.01% 6133
2024
Q2 		$2.02M Sell
86,400
-21,400
-20% -$526K ﹤0.01% 5282
2024
Q1 		$3.56M Buy
107,800
+59,300
+122% +$1.85M ﹤0.01% 4507
2023
Q4 		$1.32M Sell
48,500
-51,200
-51% -$1.27M ﹤0.01% 6117
2023
Q3 		$2.4M Buy
99,700
+40,200
+68% +$1.08M ﹤0.01% 4885
2023
Q2 		$1.9M Sell
59,500
-77,800
-57% -$2.52M ﹤0.01% 5237
2023
Q1 		$4.2M Sell
137,300
-39,200
-22% -$1.55M ﹤0.01% 4091
2022
Q4 		$6.9M Buy
176,500
+69,900
+66% +$3.13M ﹤0.01% 3350
2022
Q3 		$5.08M Buy
106,600
+9,400
+10% +$536K ﹤0.01% 3839
2022
Q2 		$3.76M Buy
97,200
+22,800
+31% +$906K ﹤0.01% 4334
2022
Q1 		$4.26M Buy
74,400
+24,100
+48% +$1.58M ﹤0.01% 4496
2021
Q4 		$4.01M Sell
50,300
-18,300
-27% -$1.57M ﹤0.01% 4740
2021
Q3 		$5.97M Buy
68,600
+26,400
+63% +$2.65M ﹤0.01% 3975
2021
Q2 		$5.43M Sell
42,200
-30,800
-42% -$2.45M ﹤0.01% 4254
2021
Q1 		$5.84M Buy
73,000
+30,400
+71% +$2.89M ﹤0.01% 3924
2020
Q4 		$3.48M Buy
+42,600
New +$2.09M ﹤0.01% 4332

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Citadel Advisors's BEAM Position: Q1 2026 in Review

Citadel Advisors increased its Beam Therapeutics (BEAM) stake by 107% in Q1 2026, buying an estimated $7.58M and bringing the position to 528,970 shares worth $12.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2921.

Citadel Advisors first reported a position in BEAM in Q1 2020 and has held it in 23 quarters since. The position peaked at $51.1M in Q4 2024. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Citadel Advisors held 528,970 shares of Beam Therapeutics worth $12.6M as of Q1 2026.
  • Citadel Advisors bought 273,260 Beam Therapeutics shares in Q1 2026, an estimated $7.58M.
  • Beam Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2921 holding.
  • Citadel Advisors first reported a position in Beam Therapeutics in Q1 2020 and has held it in 23 quarters since.
  • Citadel Advisors's Beam Therapeutics position peaked at $51.1M in Q4 2024.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.